MedTrace Logo

Safe Use of New Oral Anticoagulants in Ablation for Atrial Fibrillation

NCT02569255 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 234

Last updated 2015-10-06

No results posted yet for this study

Summary

Use of new oral anticoagulants (NOAC) in patients before and after catheter based pulmonary vein isolation (PVI) is still controversial. Experience is reported from consecutive patients ablated with PVI for atrial fibrillation and treated with dabigatran, rivaroxaban, or apixaban from Nov 2011 until Dec 2014. Patients are followed for 3 month after ablation. All complications possible being related to the use of NOAC are registered.

Conditions

Interventions

PROCEDURE

Pulmonary venous ostia isolation

Percutaneous, catheterbased, radiofrequency ablation with left atrial access via atrial septal puncture. Helped by 3D-imaging system (Carto(tm)) and electrical signal guidance the PV ostia together with neighbouring atrial tissue is electrically isolated from the rest of the left atrium.

Sponsors & Collaborators

  • Private Hospital Heart Center Varde

    lead OTHER

Principal Investigators

  • Peter S Hansen, M.D. · Varde Heart Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2014-12-31
Completion
2015-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02569255 on ClinicalTrials.gov